The Company That No Longer Trades
Dicerna Pharmaceuticals is not a stock you can buy anymore. Eli Lilly (LLY) acquired the company, and its work now lives inside Lilly’s pipeline as the Lp(a) drug lepodisiran. That is the quiet origin story behind one of the competitors in the gene-silencing race Porter Stansberry’s Ignition Point pitch revolves around.
Dicerna’s technology was called GalXC, an RNA interference platform built around the same biological machinery that won the 2006 Nobel Prize. The company used it to silence specific genes, and its early work on Lp(a) became the seed for lepodisiran, which Lilly took over and paired with a partnership alongside Novo Nordisk.
Why Lilly Bought It
Lilly did not buy Dicerna for a single drug. It bought the GalXC platform itself, the engine that could keep producing candidates against difficult targets. That is the strategic logic behind the acquisition: instead of licensing one program, Lilly wanted the capability to build a whole pipeline of RNAi drugs.
Lepodisiran is the highest-profile product of that decision. It is aimed squarely at Lp(a), the genetically determined particle that statins and diet barely move, and it sits in late-stage development as a direct competitor to the drugs at the center of Porter’s thesis.
The Lp(a) Race Gets Crowded
The Ignition Point pitch focuses on a specific set of picks, but lepodisiran is not one of them. It is a competitor, running alongside Amgen’s olpasiran and the antisense drug pelacarsen that Ionis licensed to Novartis. We frame that competitive field in our Amgen piece.
The race matters because of what happened on September 4, 2026. Novartis reported that pelacarsen lowered Lp(a) but failed to cut cardiovascular events, a reminder that a biomarker reduction is not an outcome. Lepodisiran has to clear that same bar, and its trial is now one of the most closely watched readouts in cardiovascular medicine.
The Difference a Failed Trial Makes
For Lilly, the stakes are lower than they were for Novartis’s program. Lilly is a diversified giant, and lepodisiran is one program among many. But the RNAi platform it acquired from Dicerna is a long-term bet, and the outcome of lepodisiran’s trial will tell investors a lot about whether that acquisition was money well spent.
That is the difference between owning the platform and owning a royalty. Dicerna’s former shareholders sold the science outright, giving up the option on lepodisiran’s success in exchange for Lilly’s cash and stock. The royalty aggregators take the opposite side of that trade, which is the capital-light logic Porter lays out in his broader Royalty Riches teardown.
What It Means for Investors
The Dicerna story is a reminder that the science behind a blockbuster often changes hands long before the blockbuster exists. Investors who want exposure to lepodisiran today buy Lilly, not Dicerna, and they get a diversified pharma company rather than a pure RNAi bet.
For anyone following the gene-silencing theme, the lesson is the same one the antisense side of the story teaches, which we cover in our Ionis Pharmaceuticals piece: know who invented the drug, who owns it now, and who carries the trial risk.
The Novo Nordisk Partnership
Lilly did not develop lepodisiran alone. It paired the Dicerna platform with a partnership alongside Novo Nordisk, the diabetes and obesity giant, spreading the cost and the risk of a big cardiovascular outcomes program across two of the largest drugmakers in the world. That is a signal in itself: two heavyweight companies do not jointly fund a program they think is a long shot.
The partnership also tells you something about the size of the prize. Cardiovascular outcomes trials are among the most expensive studies in medicine, running for years and enrolling tens of thousands of patients. Splitting that cost only makes sense if the drug, should it work, addresses a market measured in the millions of patients, which is exactly what a genetically inherited, statin-resistant risk factor like Lp(a) represents.
For Lilly shareholders, the arrangement changes the math. Lepodisiran is a shared bet, so the upside of a win is split, but so is the cost of a miss. The Dicerna acquisition gave Lilly the platform; the Novo Nordisk deal gave it a partner to share the burden of proving that platform works in a large outcomes trial.
The takeaway is that lepodisiran is now a consortium effort, not a Lilly-only bet. That reduces the risk to any single company’s balance sheet, and it raises the odds that the trial actually gets completed and answered, which is the real question hanging over the entire Lp(a) race. For investors, the Dicerna story is a reminder that even a blockbuster-in-waiting rarely belongs to one company by the time it reaches the market.
Ready to see the research? Click here to access Porter Stansberry’s report.
NewsletterVetter is an independent publication. We receive compensation from some of the services we review through affiliate links. Nothing on this site is investment advice. Always do your own research.